New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...
HealthDay on MSN12h
Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
For patients with resected stage IB-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer, molecular ...
European Medical Journal5d
Osimertinib’s Role in Detecting Residual Lung Cancer
Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...
A Potential Challenger For AstraZeneca's Blockbuster Lung Cancer Drug?
AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.
ascopubs.org1mon
Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
A post-treatment blood test could inform future cancer therapy decisions
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...
Medical Dialogues6d
Post-Treatment Blood Test Offers New Hope for Personalized Cancer Therapy Decisions: Study Finds
A new Yale study has found evidence to support the value of a tool that measures the presence of cancer -derived molecules in ...
National Institute for Health and Care Excellence28d
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
This evaluation reviews the evidence for osimertinib for treating NSCLC after complete tumour resection. It also reviews new evidence collected as part of the managed access agreement, which includes ...
PharmiWeb17h
New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...